Very happy to had the opportunity to present our data at the DGN in Berlin.
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
@dgn-ev.bsky.social
We had a wonderful #eano2025 in Prague, with multiple talks and poster presentations and fruitful discussions!
Looking forward to Rome!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@nihalolcaydogan.bsky.social
@hih-tuebingen.bsky.social
Now Surender Surender on stage, presenting our data on CDK4/6 inhibition in experimental glioma!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
Extremely happy that we could have contributed!
Great comprehensive talk by @ghtabatabai.bsky.social to give insights into CRISPR screen.
More to come!
@eanoassociation.bsky.social
Great talk by @ghtabatabai.bsky.social about time management in academia
@eanoassociation.bsky.social
Innovative trial design, thank you for the opportunity for being part of it!
We are very happy to present you our work, recently accepted in Neurooncology!
@ghtabatabai.bsky.social @hih-tuebingen.bsky.social
academic.oup.com/neuro-oncolo...
Glad to have the opportunity to present our data!
@eanoassociation.bsky.social
Nice opportunity to present our data on regorafenib in combination with navitoclax at @eanoassociation.bsky.social
@hannes-becker1996.bsky.social
@ghtabatabai.bsky.social
AbstractBackground. Glioblastoma harbors frequent alterations in the retinoblastoma (RB1) pathway, providing a genetic rationale for therapeutic targeting
academic.oup.com
Hannes Becker
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Hannes Becker
Neurooncology Tuebingen
We are very happy to present our data at the DGN in Berlin!
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@dgn-ev.bsky.social
And now it‘s Hannes Becker on stage, presenting our data at EANO2025 👍🏼🙌 @neurooncotue.bsky.social
Excited to announce that we have completed accrual of the INTERCEPT-H3 trial (NCT04808245). This phase 1 first-in-human trial explores safety and immunogenicity of a long peptide vaccine targeting the clonal driver mutation H3K27M in adult patients with newly diagnosed diffuse midline gliomas 1/
🧠 The phase 1/2 N2M2 umbrella trial lead by former EANO president @wickwolfgang.bsky.social has just been published in Nature Medicine
🔗 www.nature.com/articles/s41...
#NeuroOncology #EANOessentials #BrainTumors #CancerResearch
And now it‘s Hannes Becker on stage, presenting our data at EANO2025 👍🏼🙌 @neurooncotue.bsky.social
Neurooncology Tuebingen
Ghazaleh Tabatabai
EANO
Ghazaleh Tabatabai
Michael Platten, MD
In a phase 1/2a umbrella trial in patients with glioblastoma matching targeted therapies according to tumor molecular profiling, temsirolimus plus radiotherapy improved PFS compared to standard of car...
